What matters most? new study puts quality of life first for older leukemia patients
NCT ID NCT04380441
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how quality of life differs among older adults (60+) newly diagnosed with acute myeloid leukemia (AML) who receive either intensive or non-intensive chemotherapy. Researchers aim to build a decision-making model that helps patients and doctors choose treatments based on personal priorities. About 206 participants will complete a leukemia-specific quality-of-life questionnaire.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
206 people
The number who actually took part.
- Started
-
Jul 2020
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients of the Malignant Hematology Department or Senior Adult Oncology Division at Moffitt Cancer Center in Tampa, Florida.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 60 years of age or older * Newly diagnosed with pathology-confirmed diagnosis of Acute Myeloid Leukemia * Within 7 days of starting a new treatment * Must be able to read and speak English at the 8th grade level Exclusion Criteria: * Under 60 years of age * Other malignancy, dementia, traumatic brain injury or individuals with central nervous system involvement of their leukemia
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an HDAC inhibitor wipe out residual leukemia cells?
- Can an experimental pill block a cancer-driving enzyme in hard-to-treat leukemia?
- Two-Drug combo targets leukemia that outsmarted its first treatment
- Tweaking donor cells may shield older transplant patients from a dangerous complication
- Can a drug and donor cells stop leukemia from returning after transplant?
- New drug combination targets Hard-to-Treat blood cancers